Data gathered: February 9
AI Stock Analysis - Tonix Pharmaceuticals (TNXP)
Analysis generated January 15, 2025. Powered by Chat GPT.
Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies and biologics for challenging and rare diseases. The company focuses on central nervous system (CNS) conditions, immunology, infectious diseases, and oncology. Tonix employs a multi-pronged approach to drug development, including both small molecule and biologic drug candidates.
Stock Alerts - Tonix Pharmaceuticals (TNXP)
![]() |
Tonix Pharmaceuticals | February 7 Price is up by 20.2% in the last 24h. |
![]() |
Tonix Pharmaceuticals | February 6 Price is down by -6.7% in the last 24h. |
![]() |
Tonix Pharmaceuticals | February 5 Price is down by -8% in the last 24h. |
![]() |
Tonix Pharmaceuticals | February 4 Price is down by -10.2% in the last 24h. |
Alternative Data for Tonix Pharmaceuticals
Alternative Data | Value | 3m Change | Trend | Benchmark | |
---|---|---|---|---|---|
Job Posts | 7 | Sign up | Sign up | Sign up | |
Sentiment | 83 | Sign up | Sign up | Sign up | |
Webpage traffic | 70,000 | Sign up | Sign up | Sign up | |
Google Trends | 4 | Sign up | Sign up | Sign up | |
4chan Mentions | N/A | Sign up | Sign up | Sign up | |
Facebook Engagement | 31 | Sign up | Sign up | Sign up | |
Facebook Followers | 1,773 | Sign up | Sign up | Sign up | |
Reddit Mentions | N/A | Sign up | Sign up | Sign up | |
Stocktwits Mentions | 278 | Sign up | Sign up | Sign up | |
Stocktwits Subscribers | 78,702 | Sign up | Sign up | Sign up | |
Twitter Followers | 8,212 | Sign up | Sign up | Sign up | |
Twitter Mentions | 163 | Sign up | Sign up | Sign up | |
News Mentions | N/A | Sign up | Sign up | Sign up | |
Customer reviews | N/A | Sign up | Sign up | Sign up | |
Linkedin Employees | 92 | Sign up | Sign up | Sign up |
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Price | $12.39 |
Target Price | Sign up |
Volume | 10,510,000 |
Market Cap | $69M |
Year Range | $11.24 - $518.4 |
Dividend Yield | 0% |
Analyst Rating | 100% buy |
Industry | Biotechnology |
In the news
Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End CashFebruary 7 - GlobeNewswire |
|
![]() |
Tonix Pharmaceuticals announces results from Phase 1 trial for TNX-1500February 6 - Thefly.com |
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune DiseasesFebruary 6 - GlobeNewswire |
|
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor ConferenceFebruary 5 - GlobeNewswire |
|
Tonix Pharmaceuticals Announces 1-for-100 Reverse Stock SplitFebruary 3 - GlobeNewswire |
|
![]() |
Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.comFebruary 3 - ETF Daily News |
Financial performance View All
Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
---|---|---|---|---|---|---|
Q3 '24 | 2.8M | 1.6M | 1.3M | -14M | -15M | -0.229 |
Q2 '24 | 2.2M | 3.4M | -1.2M | -79M | -76M | -19.280 |
Q1 '24 | 9.5M | 1.7M | 7.8M | -15M | -20M | -0.180 |
Q4 '23 | 3.6M | 2.4M | 1.3M | -27M | -26M | -0.860 |
Q3 '23 | 4M | 2.4M | 1.6M | -28M | -27M | -1.830 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Tonix Pharmaceuticals (TNXP) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Tonix Pharmaceuticals?
The Market Cap of Tonix Pharmaceuticals is $69M.
What is the current stock price of Tonix Pharmaceuticals?
Currently, the price of one share of Tonix Pharmaceuticals stock is $12.39.
How can I analyze the TNXP stock price chart for investment decisions?
The TNXP stock price chart above provides a comprehensive visual representation of Tonix Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tonix Pharmaceuticals shares. Our platform offers an up-to-date TNXP stock price chart, along with technical data analysis and alternative data insights.
Does TNXP offer dividends to its shareholders?
As of our latest update, Tonix Pharmaceuticals (TNXP) does not offer dividends to its shareholders. Investors interested in Tonix Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Tonix Pharmaceuticals?
Some of the similar stocks of Tonix Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.